TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes
Brief Summary: The PHF trial will assess the acceptability and long term outcomes resulting from the usage of electronic (carried by the patient on a USB memory device) and paper portable health files in a population with high intensity use of medical services. The rationale is that use of the portable health files provides a conduit of direct communication among health care providers of a patient's important health care information and this leads to better care and patient outcomes.

Primary hypothesis: Addition of a patient-held portable health file (PHF) to usual care improves patient outcome and quality-of-life compared to usual care alone.

Secondary hypothesis: Addition of patient-held portable health file (PHF) to usual care is acceptable and satisfactory to patients and their health care providers.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual diabetes and depression care | Arm Label: TeamCare Depression Intervention; Type: EXPERIMENTAL; Interventions: Other: TeamCare Depression Intervention | Intervention Type: OTHER; Name: TeamCare Depression Intervention; Assigned to Arm(s): TeamCare Depression Intervention | Intervention Type: OTHER; Name: Usual diabetes and depression care; Assigned to Arm(s): Usual Care
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
C: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Arm Label: Standardized educational plan; Type: EXPERIMENTAL; Interventions: Other: Standardized educational plan | Intervention Type: OTHER; Name: Standardized educational plan; Assigned to Arm(s): Standardized educational plan | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
D: Arm Label: Electronic (USB) Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Electronic (USB) Portable Health File | Arm Label: Paper Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Paper Portable Health File | Arm Label: Usual standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic (USB) Portable Health File; Assigned to Arm(s): Electronic (USB) Portable Health File | Intervention Type: DEVICE; Name: Paper Portable Health File; Assigned to Arm(s): Paper Portable Health File

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes
Brief Summary: The PHF trial will assess the acceptability and long term outcomes resulting from the usage of electronic (carried by the patient on a USB memory device) and paper portable health files in a population with high intensity use of medical services. The rationale is that use of the portable health files provides a conduit of direct communication among health care providers of a patient's important health care information and this leads to better care and patient outcomes.

Primary hypothesis: Addition of a patient-held portable health file (PHF) to usual care improves patient outcome and quality-of-life compared to usual care alone.

Secondary hypothesis: Addition of patient-held portable health file (PHF) to usual care is acceptable and satisfactory to patients and their health care providers.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
B: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching by medical assistants in primary care | Intervention Type: BEHAVIORAL; Name: Health coaching by medical assistants in primary care; Assigned to Arm(s): Health Coaching
C: Arm Label: Index group; Type: ACTIVE_COMPARATOR; Interventions: Other: Index group | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Index group; Assigned to Arm(s): Index group
D: Arm Label: Electronic (USB) Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Electronic (USB) Portable Health File | Arm Label: Paper Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Paper Portable Health File | Arm Label: Usual standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic (USB) Portable Health File; Assigned to Arm(s): Electronic (USB) Portable Health File | Intervention Type: DEVICE; Name: Paper Portable Health File; Assigned to Arm(s): Paper Portable Health File

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis
Brief Summary: The aim of the study is correlating efficacy of the treatment to the proportion of paclitaxel-dose supplied by the catheter. Forty-five patients each will be treated by paclitaxel-coated or uncoated conventional balloon catheters in randomized order in 3 study centers. Main inclusion criteria are Rutherford class 2 - 5, ≥70% stenosis or occlusion in the superficial femoral or popliteal artery, main exclusion criteria are related to the use of paclitaxel and the need for follow-up examinations. Either clinical or angiographic follow-up examinations are planned 6, 12 and 24 months following the intervention. Primary endpoint is 6-month angiographic late lumen loss. Secondary endpoints are further angiographic and clinical efficacy and various safety criteria.


Options:
A: Arm Label: Conventional PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous transluminal angioplasty (PTA) | Arm Label: Drug coated balloon; Type: EXPERIMENTAL; Interventions: Combination Product: DCB | Intervention Type: DEVICE; Name: Percutaneous transluminal angioplasty (PTA); Assigned to Arm(s): Conventional PTA | Intervention Type: COMBINATION_PRODUCT; Name: DCB; Assigned to Arm(s): Drug coated balloon
B: Arm Label: Drug-Coated Balloon (DCB); Type: EXPERIMENTAL; Interventions: Device: Drug-Coated Balloon (DCB) | Arm Label: Standard PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA Balloon: Balloon Angioplasty | Intervention Type: DEVICE; Name: Drug-Coated Balloon (DCB); Assigned to Arm(s): Drug-Coated Balloon (DCB) | Intervention Type: DEVICE; Name: PTA Balloon: Balloon Angioplasty; Assigned to Arm(s): Standard PTA
C: Arm Label: Passeo-18 Lux DRB; Type: EXPERIMENTAL; Interventions: Device: Passeo-18 Lux DRB | Arm Label: Standard PTA (POBA); Type: ACTIVE_COMPARATOR; Interventions: Device: Standard PTA (POBA) | Intervention Type: DEVICE; Name: Passeo-18 Lux DRB; Assigned to Arm(s): Passeo-18 Lux DRB | Intervention Type: DEVICE; Name: Standard PTA (POBA); Assigned to Arm(s): Standard PTA (POBA)
D: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS)
Brief Summary: The aim of this study is to perform a randomized, controlled trial to compare percutaneous transluminal angioplasty using paclitaxel eluting balloon (PEB) or using a conventional balloon for treatment of superficial femoral artery in-stent restenosis.


Options:
A: Arm Label: Laser atherectomy and PTA; Type: EXPERIMENTAL; Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters | Arm Label: Balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Balloon angioplasty | Intervention Type: DEVICE; Name: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Assigned to Arm(s): Laser atherectomy and PTA | Intervention Type: PROCEDURE; Name: Balloon angioplasty; Assigned to Arm(s): Balloon angioplasty
B: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA
C: Arm Label: Paclitaxel eluting balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting balloon angioplasty | Arm Label: Standard balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: standard balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting balloon angioplasty; Assigned to Arm(s): Paclitaxel eluting balloon | Intervention Type: DEVICE; Name: standard balloon angioplasty; Assigned to Arm(s): Standard balloon angioplasty
D: Arm Label: conventional PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA, Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: PTA with PEB; Type: EXPERIMENTAL; Interventions: Device: PTA with PEB, Procedure: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): conventional PTA | Intervention Type: DEVICE; Name: PTA with PEB; Assigned to Arm(s): PTA with PEB | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA with PEB, conventional PTA

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Care Interventions With 0.12% Chlorhexidine and Ventilator Associated Pneumonia in Critically Ill Children: Prospective, Randomic and Double Blind Study
Brief Summary: This experimental study aims to verify the influence of the oral hygiene performance with chlorhexidine digluconate 0.12% in the development of VAP in children. The data collection begun in April, 2005 during the performance of the masters degree course dissertation entitled "Clinical study about the effect of the oral hygiene with chlorhexidine digluconate 0.12% in the oropharynx colonization of children in intensive care", being performed in a PICU of nine beds in a university hospital in the city of São Paulo, after approval of the Research Ethics Committee of the institution. The study is composed by three types of variables: Independent variable, dependent variables, and complementary variables. The categorical variables will be analyzed in accordance with the Person's Chi-Square test of or Fisher's exact test. The numerics will be submitted to the analysis of variance ANOVA or Kruskall Wallis. For variables with heterogeneous distribution between the groups, the multivariate analysis will be applied to the evaluation of the influence in the determination of the development risk of the dependent variable. The rejection level will be fixed in 0.05 of the nullity hypothesis.


Options:
A: Arm Label: 0.12% Chlorhexidie Digluconate; Type: EXPERIMENTAL; Interventions: Drug: 0.12% Chlorhexidine Digluconate | Arm Label: Toothbrushing; Type: PLACEBO_COMPARATOR; Interventions: Other: Toothbrushing | Intervention Type: DRUG; Name: 0.12% Chlorhexidine Digluconate; Assigned to Arm(s): 0.12% Chlorhexidie Digluconate | Intervention Type: OTHER; Name: Toothbrushing; Assigned to Arm(s): Toothbrushing
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Oral Care | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Comprehensive Oral Care | Intervention Type: PROCEDURE; Name: Standard Oral Care; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Comprehensive Oral Care; Assigned to Arm(s): B
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: oral hygiene | Intervention Type: OTHER; Name: oral hygiene; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: Raspall; Type: EXPERIMENTAL; Interventions: Procedure: Toothbrushing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Toothbrushing; Assigned to Arm(s): Raspall

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Care Interventions With 0.12% Chlorhexidine and Ventilator Associated Pneumonia in Critically Ill Children: Prospective, Randomic and Double Blind Study
Brief Summary: This experimental study aims to verify the influence of the oral hygiene performance with chlorhexidine digluconate 0.12% in the development of VAP in children. The data collection begun in April, 2005 during the performance of the masters degree course dissertation entitled "Clinical study about the effect of the oral hygiene with chlorhexidine digluconate 0.12% in the oropharynx colonization of children in intensive care", being performed in a PICU of nine beds in a university hospital in the city of São Paulo, after approval of the Research Ethics Committee of the institution. The study is composed by three types of variables: Independent variable, dependent variables, and complementary variables. The categorical variables will be analyzed in accordance with the Person's Chi-Square test of or Fisher's exact test. The numerics will be submitted to the analysis of variance ANOVA or Kruskall Wallis. For variables with heterogeneous distribution between the groups, the multivariate analysis will be applied to the evaluation of the influence in the determination of the development risk of the dependent variable. The rejection level will be fixed in 0.05 of the nullity hypothesis.


Options:
A: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm
B: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
C: Arm Label: 0.12% Chlorhexidie Digluconate; Type: EXPERIMENTAL; Interventions: Drug: 0.12% Chlorhexidine Digluconate | Arm Label: Toothbrushing; Type: PLACEBO_COMPARATOR; Interventions: Other: Toothbrushing | Intervention Type: DRUG; Name: 0.12% Chlorhexidine Digluconate; Assigned to Arm(s): 0.12% Chlorhexidie Digluconate | Intervention Type: OTHER; Name: Toothbrushing; Assigned to Arm(s): Toothbrushing
D: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama
Brief Summary: The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).


Options:
A: Arm Label: Intralesional antimony; Type: EXPERIMENTAL; Interventions: Drug: pentavalent antimony | Arm Label: Cryotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: cryotherapy | Arm Label: Topical cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo cream | Intervention Type: DRUG; Name: pentavalent antimony; Assigned to Arm(s): Intralesional antimony | Intervention Type: PROCEDURE; Name: cryotherapy; Assigned to Arm(s): Cryotherapy | Intervention Type: DRUG; Name: placebo cream; Assigned to Arm(s): Topical cream
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miltefosine | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meglumine antimoniate | Intervention Type: DRUG; Name: Miltefosine; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Meglumine antimoniate; Assigned to Arm(s): Group 2
C: Arm Label: Group 1 - Paromomycin cream; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Sulfate | Arm Label: Group 2. Local Injectable Pentamidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentamidine Isethionate | Arm Label: Group 3. Vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Paromomycin Sulfate; Assigned to Arm(s): Group 1 - Paromomycin cream | Intervention Type: DRUG; Name: Pentamidine Isethionate; Assigned to Arm(s): Group 2. Local Injectable Pentamidine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 3. Vehicle control
D: Arm Label: Paromomycin Alone Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paromomycin Alone Cream (15% paromomycin topical cream) | Arm Label: WR 279,396; Type: ACTIVE_COMPARATOR; Interventions: Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) | Intervention Type: DRUG; Name: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Paromomycin Alone Cream (15% paromomycin topical cream); Assigned to Arm(s): Paromomycin Alone Treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin (5 mg) Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients (Age >= 70 Years) With Insufficient Glycaemic Control( HbA1c >= 7.0) Despite Metformin and/or Sulphonylurea and/or Insulin Therapy
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control


Options:
A: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
B: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride
D: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of the Use of Antenatal Corticosteroids in Developing Countries
Brief Summary: Multi-country two-arm, parallel cluster randomized controlled trial to reduce neonatal mortality through increasing the rate of antenatal corticosteroid administration to eligible women.


Options:
A: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
C: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
D: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)

Answer: B